Abstract
The tumor microenvironment (TME) is a pivotal regulator of carcinogenesis, progression, and therapeutic response. This complex niche, comprised of immune cells, cancer-associated fibroblasts, extracellular matrix, and signaling molecules, fosters immunosuppression and facilitates immune evasion through the recruitment and activation of cells like tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs). A key mechanism of this evasion is the expression of immune checkpoint molecules, including PD-1(programmed death receptor-1)/PD-L1(programmed death ligand-1) and CTLA-4, which inhibit anti-tumor immunity. Although immune checkpoint inhibitors have demonstrated remarkable clinical success, their efficacy is variable and often hampered by the high heterogeneity and adaptive resistance of the TME. Emerging strategies, such as targeting metabolic pathways, gut microbiota, and employing combination therapies, are being explored to reprogram the TME and overcome resistance. This review comprehensively outlines the composition of the TME, its role in driving tumor progression and immunotherapy response, and discusses future directions, emphasizing that a deeper understanding of the TME is essential for developing novel and personalized cancer immunotherapies.